Oppenheimer Maintains Outperform on TransMedics Gr, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $125 to $200.
August 01, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group and raises the price target from $125 to $200.
The raised price target from $125 to $200 by a reputable analyst at Oppenheimer is a strong positive signal for investors. This suggests confidence in the company's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100